11/05/2025
๐๐ฎ๐ฟ๐น๐ ๐๐ถ๐ฎ๐ด๐ป๐ผ๐๐ถ๐ ๐ฎ๐ป๐ฑ ๐ง๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐ ๐ฃ๐๐ ๐๐ด๐ฒ-๐๐
๐ฝ๐ฒ๐ฐ๐๐ฒ๐ฑ ๐๐ผ๐ป๐ด๐ฒ๐๐ถ๐๐ ๐๐ถ๐๐ต๐ถ๐ป ๐ฅ๐ฒ๐ฎ๐ฐ๐ต ๐ณ๐ผ๐ฟ ๐ฃ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐๐ถ๐๐ต ๐๐ง๐ง๐ฅ-๐๐ .
A striking analysis by Brett W. Sperry, MD, FASNC, overlays survival curves from landmark amyloidosis trials with U.S. age-expected mortalityโand the lines nearly meet.
๐ The key: early, accurate diagnosis and modern treatments show not only improved survival but measurable improvements in cardiac structure and function.
As Michelle M. Kittleson, MD, PhD, notes, โWe are entering an era where patients should expect not to die ๐ง๐ณ๐ฐ๐ฎ cardiac amyloidosis but rather ๐ธ๐ช๐ต๐ฉ it.โ
Read now๐https://bit.ly/4qBtZid
Sponsored by Alnylam Pharmaceuticals.